Radius
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
22 Boston Wharf Rd Fl 7, Boston, Massach...Phone Number
(617) 583-2017Website
www.radiuspharm.comRevenue
$230 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
6
1
1
1
1
About Radius
Radius is a biopharmaceutical company founded in 2003 and is located in Boston, Massachusetts. The company is focused on developing therapeutics for oncology, endocrine diseases, and osteoporosis.Explore more
Radius Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Radius your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Radius has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Radius recently announced quarterly report
Funding: Get notified immidiatlly once Radius has new funding data
Product Launch: Get notified when Radius launches new products
Check out if Radius is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Radius
Click to see if Radius had a recent Job posting/layoffs
Radius, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Radius as Masked Content
Find 2 more new buyers
Compare Similar Companies to Radius
Compare insights from companies similar to Radius, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Radius is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Radius is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Radius.
Radius financials insights
Gather financial insights about Radius, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series B
$57.5M
2008
Series C
$82.5M
2011
Debt
$25M
Private Equity
$21.4M
2013
Private Equity
$43M
2014
Stock Offering
$52M
2021
Debt
$175M
2022
Debt
$350M
Radius Tech Stack
A closer look at the technologies used by Radius
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Pain Point
Project
, according to a mid-level source in management & operations, is planning to remediate challenges related to generating more leads and pipeline. Radius is planning to increase headcount.
Pain Point, Lead Management, Sales Development, Operations
Project
, according to a mid-level source in management & operations, is in the midst of initiatives related to collaboration. Radius will be increasing funding to support these efforts. These efforts are focused on engaging team member participation.
Spending/Investment, Collaboration/Web Apps, Financial Planning, Funding, Employee Relations, Finance, Operations
Pain Point
Project
, according to a mid-level source in management & operations, is planning to remediate challenges related to expanding into new geo-regions. Radius is planning to increase funding.
Pain Point, Spending/Investment, Financial Planning, Funding, Business Development, Finance, Operations
Project
Spending/Investment, Engineering, Analytics & Insights, Financial Planning, Funding, Workforce Management, Finance, Operations
Radius News & Media
EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States
FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced that it has signed an exclusive licensing and distribution agreement with Radius Health, Inc for Binosto® for the United States. BINOSTO® is indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. BINOSTO® provRadius Announces Royalty Purchase Agreement With DRI Healthcare to Sell a Portion of Its Royalty and Commercial Milestone Interest in elacestrant for up to $140 Million
BOSTON--(BUSINESS WIRE)--Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. (“Radius” or the “Company”), a specialty biopharmaceutical company focused on bone health, announced today that it has entered into a Royalty Purchase Agreement for a portion of Radius’s royalty and commercial milestone stream in elacestrant, the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or metastatic breast cancer, with DRI Healthcare Acquisitions LP (“DRI HealtTheramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia and Brazil
LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United KingdRadius Health's TYMLOS® (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
CAMBRIDGE, Mass., Dec. 20, 2022 /PRNewswire/ -- Radius Health, Inc. ("Radius" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved TYMLOS® (abaloparatide), a parathyroid hormone related peptide [PTHrP(1‑34)] analog, as a treatment to increase...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Radius
Sign Up For FreeTo access detailed company insights
Radius is a biopharmaceutical company founded in 2003 and is located in Boston, Massachusetts. The company is focused on developing therapeutics for oncology, endocrine diseases, and osteoporosis.... Read More
